ECX Stock Overview
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer.
+ 1 more risk
Epigenomics AG Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€0.47|
|52 Week High||€1.34|
|52 Week Low||€0.38|
|1 Month Change||2.62%|
|3 Month Change||-5.81%|
|1 Year Change||-59.97%|
|3 Year Change||-96.49%|
|5 Year Change||-98.58%|
|Change since IPO||-98.38%|
Recent News & Updates
|ECX||DE Biotechs||DE Market|
Return vs Industry: ECX underperformed the German Biotechs industry which returned -3% over the past year.
Return vs Market: ECX underperformed the German Market which returned -20.8% over the past year.
|ECX Average Weekly Movement||9.1%|
|Biotechs Industry Average Movement||8.7%|
|Market Average Movement||5.6%|
|10% most volatile stocks in DE Market||10.4%|
|10% least volatile stocks in DE Market||2.8%|
Stable Share Price: ECX is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ECX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.
Epigenomics AG Fundamentals Summary
|ECX fundamental statistics|
Is ECX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ECX income statement (TTM)|
|Cost of Revenue||€139.00k|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 10, 2022
|Earnings per share (EPS)||-0.24|
|Net Profit Margin||-62.52%|
How did ECX perform over the long term?See historical performance and comparison